胸主动脉腔内修复术治疗降主动脉瘤的长期结局:基于FDA临床试验汇总结果
本研究为单中心回顾性研究,纳入2000至2019年参加14项FDA临床试验的179例降主动脉瘤TEVAR患者,评估长期结局。10年生存率31.4%,内漏和再干预与10年全因死亡无关,年龄和术前瘤径是死亡的独立预测因素,73.8%患者5年时瘤囊稳定。作者认为在该老年队列中TEVAR耐久性仍值得关注。
要点
- TEVAR术后1、5、10年生存率分别为91.1%、62.8%、31.4%。
- 内漏发生58例(32.4%),再干预44例(24.6%),均与10年全因死亡无关。
- 年龄增长和术前瘤径是死亡的独立预测因素,73.8%患者5年瘤囊稳定。
核心结论
- 尽管10年总体生存有限,但早期结局良好,大多数患者5年时瘤囊稳定。
- 内漏和再干预与长期死亡无关,而年龄和术前主动脉直径预测更差生存。
- 在该老年患者队列中,TEVAR的耐久性仍值得关注。
研究设计与样本
- 单中心回顾性研究,纳入2000至2019年间参加14项FDA研究器械豁免临床试验的降主动脉瘤TEVAR患者179例。
- 主要结局为10年死亡率,次要结局包括30天死亡或神经事件复合终点、内漏、再干预和随访影像上的主动脉直径。
- 采用描述性统计、Kaplan-Meier生存分析、Cox比例风险模型和竞争风险累积发生率函数进行分析。
主要发现
- 患者中位年龄74岁,中位随访5.5年。
- 动脉瘤形态为梭形(n=100[55.9%])或囊状(n=70[39.1%]),术前中位直径60.0 mm。
- 1、5、10年生存率分别为91.1%、62.8%、31.4%。
- 内漏见于58例(32.4%),再干预见于44例(24.6%)。
- 内漏和再干预均与10年全因死亡无关,年龄增长和术前动脉瘤直径是死亡的独立预测因素,73.8%患者5年时瘤囊稳定。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Thoracic endovascular aortic repair (TEVAR) is the preferred treatment for descending thoracic aortic aneurysms, but long-term data are limited. This study assessed long-term results of TEVAR in early recipients of TEVAR devices who were enrolled in US Food and Drug Administration investigational device exemption clinical trials for aneurysm. METHODS: This was a single-center retrospective study including 179 patients enrolled in 14 clinical trials for TEVAR for descending thoracic aortic aneurysm between 2000 and 2019. The primary outcome was 10-year mortality. Secondary outcomes included a 30-day composite of death or a neurologic event, endoleak, reintervention, and aortic diameter on follow-up imaging. Descriptive statistics, Kaplan-Meier survival analysis, Cox proportional hazards models, and cumulative incidence functions with competing risk were used for analysis. RESULTS: The median patient age was 74 years and median follow-up was 5.5 years. Aneurysm morphology was fusiform (n = 100 [55.9%]) or saccular (n = 70 [39.1%]), with median preoperative diameter of 60.0 mm. Survival at 1, 5, and 10 years was 91.1%, 62.8%, and 31.4%. Endoleak was observed in 58 patients (32.4%), and reintervention in 44 patients (24.6%). Neither endoleak nor reintervention was associated with all-cause mortality at 10 years. Increasing age and preoperative aneurysm diameter were independent predictors of mortality. A majority of patients (73.8%) had stable aneurysm sac at 5 years. CONCLUSIONS: Although overall survival at 10 years was limited, early outcomes were favorable and most patients had stable aneurysm sac at 5 years. Endoleak and reintervention were not linked to long-term mortality, whereas age and preoperative aortic diameter predicted worse survival. In this older patient cohort, the durability of TEVAR remains a concern.
引用
- Gillinov LA, Wang GJ, Goel NJ, et al. Long-term outcomes of thoracic endovascular aortic repair for descending thoracic aortic aneurysms based on pooled results from FDA clinical trials. J Vasc Surg. 2025. PMID: 40436328. doi:10.1016/j.jvs.2025.05.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。